checkAd
    Startseite > Aktien > Candel Therapeutics > Nachrichten
    Candel Therapeutics Aktie
    8,9000
     
    USD
    +3,37 %
    +0,2900 USD
    Letzter Kurs 02:00:00 NYSE
    8,6800
     
    USD
    100 STK
    Geldkurs 31.05.24
    9,0100
     
    USD
    600 STK
    Briefkurs 31.05.24
    ISIN: US1374041093 · WKN: A3CVW2 · SYM: CADL · USA

    Neueste Nachrichten

    FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
    30.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
    23.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
    22.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
    20.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    14.05.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
    25.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    11.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
    09.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    04.04.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
    28.03.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
    28.03.24 · globenewswire · Candel Therapeutics
    Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
    05.03.24 · globenewswire · Candel Therapeutics